Patents Assigned to Genentech
  • ALKYNYL ALCOHOLS AND METHODS OF USE
    Publication number: 20150057260
    Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: August 22, 2014
    Publication date: February 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Nicole Blaquiere, Georgette Castanedo, Jianwen A. Feng, Baihua Hu, Steven Staben, Po-wai Yuen, Guosheng Wu, Xingyu Lin, Jason Burch
  • DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
    Publication number: 20150056190
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Priti Hegde, Maike Schmidt, Ru-Fang Yeh
  • ANTIBODY PURIFICATION BY CATION EXCHANGE CHROMATOGRAPHY
    Publication number: 20150056196
    Abstract: A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 26, 2015
    Applicant: GENENTECH, INC.
    Inventors: Benedicte Andree Lebreton, Deborah Ann O'Connor, Aurelia Safta, Mandakini Sharma
  • IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR
    Publication number: 20150056132
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.
    Type: Application
    Filed: May 27, 2014
    Publication date: February 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mark DENNIS, Jan Marik, Paul Polakis, Bonnee Rubinfeld, Simon Williams
  • High concentration antibody and protein formulations
    Patent number: 8961964
    Abstract: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: February 24, 2015
    Assignee: Genentech, Inc.
    Inventors: Jun Liu, Steven J. Shire
  • Methods for detecting and treating systemic lupus erythematous
    Patent number: 8962249
    Abstract: The invention provides methods and compositions useful for detecting autoimmune disorders.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: February 24, 2015
    Assignee: Genentech, Inc.
    Inventors: Alexander Abbas, Barmak Modrek, Michael J. Townsend
  • Anti-?5?1 antibodies and uses thereof
    Patent number: 8962275
    Abstract: The present invention provides new anti-?5?1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: February 24, 2015
    Assignee: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS
    Publication number: 20150051380
    Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.
    Type: Application
    Filed: October 30, 2014
    Publication date: February 19, 2015
    Applicant: Genentech, Inc.
    Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina, Robert L. Cohen
  • PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
    Publication number: 20150051238
    Abstract: Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Applicant: GENENTECH, INC.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Bryan K. Chan, Mark Chambers, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS
    Publication number: 20150051201
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Applicant: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Bryan K. Chan, Jennafer Dotson, Anthony Estrada, Timothy Heffron, Joseph Lyssikatos, Zachary Sweeney
  • PURIFICATION OF ANTI-C-MET ANTIBODIES
    Publication number: 20150050275
    Abstract: Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same.
    Type: Application
    Filed: October 10, 2014
    Publication date: February 19, 2015
    Applicant: GENENTECH, INC.
    Inventors: Marc Wong, Jerome Joseph Bill, JR., Arick Michael Brown, Glen Scott Giese, Judy Fay-Chen Hsii, Amy Lim, Josefine Persson, Asha Nandini Radhamohan, Maricel Rodriguez
  • Binding polypeptides and uses thereof
    Patent number: 8957187
    Abstract: The invention provides antibodies or antigen binding fragments thereof to DR5 and HER-2. The antibodies and/or antigen binding fragments thereof comprise variant CDRs comprising highly restricted amino acid sequence diversity. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. In addition, compositions and methods of use for treatment of cancer and immune related conditions are provided.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: February 17, 2015
    Assignee: Genentech, Inc.
    Inventors: Sachdev S. Sidhu, Sara C. Birtalan, Frederic A. Fellouse
  • Diagnosis of malignant neoplasms using anti-Notch3 antibodies
    Patent number: 8956811
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: February 17, 2015
    Assignee: Genentech Inc.
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • COMPOSITIONS AND METHOD FOR TREATING COMPLIMENT-ASSOCIATED CONDITIONS
    Publication number: 20150044205
    Abstract: The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.
    Type: Application
    Filed: August 11, 2014
    Publication date: February 12, 2015
    Applicant: GENENTECH, INC.
    Inventors: Brian Yaspan, Robert Royal Graham, Amy Dressen, Zhengrong Li, Erich Strauss, Teodorica Bugawan
  • REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
    Publication number: 20150044198
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Application
    Filed: March 7, 2014
    Publication date: February 12, 2015
    Applicants: Novartis AG, Genentech, Inc.
    Inventors: Jun LIU, Steven J. SHIRE
  • N-substituted benzamides and methods of use thereof
    Patent number: 8952169
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: February 10, 2015
    Assignees: Xenon Pharmaceuticals Inc., Genentech, Inc.
    Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
  • 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor
    Publication number: 20150038460
    Abstract: The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Genentech, Inc.
    Inventors: Steven Staben, Jianwen Feng, Pui Leng Loke, Christian A.G.N. Montalbetti
  • TREATMENT OF METASTIC BREAST CANCER
    Publication number: 20150037332
    Abstract: The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Virginia Paton, Anne Blackwood Chirchir, Pam Klein
  • METHOD FOR PREPARING A COMPOSITION COMPRISING HIGHLY CONCENTRATED ANTIBODIES BY ULTRAFILTRATION
    Publication number: 20150037319
    Abstract: The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.
    Type: Application
    Filed: August 31, 2012
    Publication date: February 5, 2015
    Applicants: Genentech, Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kelby Lau, Jean Bender, Saeko Tanaka, Rumiko Wakayama, Hidenari Yamada, Tomonori Isoda, Masayoshi Oh-Eda
  • Alkylated piperazine compounds
    Patent number: 8946213
    Abstract: Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating cancer mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of cancer in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: February 3, 2015
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Wendy B. Young